Literature DB >> 22843987

Recombinant oncolytic adenovirus H101 combined with siBCL2: cytotoxic effect on uveal melanoma cell lines.

Xiaolin Huang1, Renbing Jia, Xiaoping Zhao, Bo Liu, Haibo Wang, Jing Wang, Yixiong Zhou, Biyun Cun, Shengfang Ge, Xianqun Fan.   

Abstract

BACKGROUND: Deregulation of Bcl2 pathway is implicated in the pathogenesis of uveal melanoma (UM). Oncolytic adenovirus H101 is the world's first oncolytic viral therapy for cancer approved for clinical use. We aimed to explore a potential synergy of downregulating Bcl2 pathway using a small interfering RNA (siBCL2) combined with H101 therapy on UM cell lines.
METHODS: The sensitivity to adenovirus infection was analysed by flow cytometry. PCR, real-time-PCR and western blot were used to detect Bcl2, p53, Bax and fibre expression. Appropriate multiplicity of H101 infection and cell survival rate were measured by a cell counting kit-8 assay. UM cells were stained with Annexin-V and propidium iodide for apoptosis assay and cell cycle distribution.
RESULTS: VUP cells (without elevation of Bcl2) exhibited greater sensitivity to adenovirus infection than OM431 cells (Bcl2 elevated cell line). Bcl2 expression was markedly reduced by siBCL2 or siBCL2 plus H101. Combined treatment with siBCL2 and H101 produced substantial growth inhibition of OM431 cells by enhancing apoptosis and cell cycle arrest through Bax-p53-induced apoptotic pathway.
CONCLUSIONS: SiBCL2 and H101 exhibited synergistic cytotoxic effect in Bcl2 elevated UM cell lines and could potentially serve as a novel targeted molecular therapy for UM.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22843987     DOI: 10.1136/bjophthalmol-2011-301470

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  10 in total

1.  The role of Bax and Bcl-2 in gemcitabine-mediated cytotoxicity in uveal melanoma cells.

Authors:  Jing Wang; Renbing Jia; Yidan Zhang; Xiaofang Xu; Xin Song; Yixiong Zhou; He Zhang; Shengfang Ge; Xianqun Fan
Journal:  Tumour Biol       Date:  2013-09-07

2.  Tumor-targeting TRAIL expression mediated by miRNA response elements suppressed growth of uveal melanoma cells.

Authors:  Jia Liu; Leina Ma; Caixin Li; Ziyu Zhang; Guanghua Yang; Wenwei Zhang
Journal:  Mol Oncol       Date:  2013-08-16       Impact factor: 6.603

3.  ECHO-7 oncolytic virus Rigvir® in an adjuvant setting for stage I uveal melanoma; A retrospective case report.

Authors:  Inta Jaunalksne; Linda Brokāne; Donatas Petroška; Agnija Rasa; Pēteris Alberts
Journal:  Am J Ophthalmol Case Rep       Date:  2020-01-31

4.  Antitumor Efficacy of Oncolytic Herpes Virus Type 1 Armed with GM-CSF in Murine Uveal Melanoma Xenografts.

Authors:  Sisi Liu; Fusheng Liu; Mingwei Zhao; Junwen Zhang
Journal:  Cancer Manag Res       Date:  2020-11-18       Impact factor: 3.989

5.  Effects of inhibition of hedgehog signaling on cell growth and migration of uveal melanoma cells.

Authors:  Fei Duan; Ming Lin; Chuanyin Li; Xia Ding; Guanxiang Qian; He Zhang; Shengfang Ge; Xianqun Fan; Jin Li
Journal:  Cancer Biol Ther       Date:  2014-03-11       Impact factor: 4.742

6.  Therapeutic improvement of a stroma-targeted CRAd by incorporating motives responsive to the melanoma microenvironment.

Authors:  Diego L Viale; Eduardo G Cafferata; David Gould; Cecilia Rotondaro; Yuti Chernajovsky; David T Curiel; Osvaldo L Podhajcer; M Veronica Lopez
Journal:  J Invest Dermatol       Date:  2013-04-19       Impact factor: 8.551

7.  Therapeutic efficacy by targeting correction of Notch1-induced aberrants in uveal tumors.

Authors:  Xiaolin Huang; Li Wang; He Zhang; Haibo Wang; Xiaoping Zhao; Guanxiang Qian; Jifan Hu; Shengfang Ge; Xianqun Fan
Journal:  PLoS One       Date:  2012-08-28       Impact factor: 3.240

Review 8.  The biology of uveal melanoma.

Authors:  Adriana Amaro; Rosaria Gangemi; Francesca Piaggio; Giovanna Angelini; Gaia Barisione; Silvano Ferrini; Ulrich Pfeffer
Journal:  Cancer Metastasis Rev       Date:  2017-03       Impact factor: 9.264

Review 9.  Oncolytic Virotherapy: From Bench to Bedside.

Authors:  Ludi Yang; Xiang Gu; Jie Yu; Shengfang Ge; Xianqun Fan
Journal:  Front Cell Dev Biol       Date:  2021-11-26

10.  The efficacy and safety of oncolytic viruses in the treatment of intermediate to advanced solid tumors: a systematic review and meta-analysis.

Authors:  Peng Gao; Guanxiong Ding; Lujia Wang
Journal:  Transl Cancer Res       Date:  2021-10       Impact factor: 1.241

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.